SECURITIES AND EXCHANGE COMMISSION
Washington, DC20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 10, 2012
Commission File Number: 000-53750
PROTEONOMIX, INC.
(Name of Registrant in Its Charter)
Delaware (State or Other Jurisdiction ofIncorporation or Organization) | 13-3842844 (I.R.S. Employer Identification No.) |
145 Highview Terrace, Hawthorne, NJ 07506
(Address of Principal Executive Offices) (Zip Code)
(973) 544-6116
(Issuer’s Telephone Number, Including Area Code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 1 – Registrant’s Business and Operations
Item 1.02 Termination of a Material Definitive Agreement
On April 10, 2012, the University of Miami (“University”) terminated the Research Agreement (“Agreement”) between the University and the Registrant, Proteonomix, Inc. (the “Company”) by delivering written notice of the termination to the Company. The purpose of the Agreement was to govern the conduct of a Phase 1 Clinical Trial of UMK-121, a combination drug therapy to be tested upon patients with End Stage Liver Disease (“ESLD”).
The Agreement was terminated by the University for “various business reasons” which were not further specified. All funds paid to the University to perform the Phase 1 Trial were returned.
Ian McNiece, a director of the Company and the Company’s Chief Scientific Officer is employed by the University as a Professor of Medicine.
Section 8. Other Events
Item 8.01 Other Events
The Company has scheduled meetings aimed at finding another institution to conduct the Phase 1 Clinical Trial of UMK-121.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROTEONOMIX, INC.
Dated: April 11, 2012
By:/s/Michael Cohen
Name: Michael Cohen
President